Harvard Bioscience Finalizes 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

Harvard Bioscience announced its stockholders approved a 1-for-10 reverse stock split, which the Board has finalized to take effect on March 13, 2026, aimed at increasing its share price to meet Nasdaq's minimum bid requirement.

check_boxKey Events

• Stockholders Approve Reverse Split

  At a Special Meeting on March 6, 2026, stockholders approved an amendment to the Company's Charter to effect a reverse stock split, with 27,004,721 votes for the proposal.

• Board Finalizes 1-for-10 Ratio

  Following stockholder approval, the Board of Directors approved a final reverse stock split ratio of 1-for-10.

• Reverse Split Effective March 13, 2026

  The reverse stock split will become effective at 4:30 p.m. Eastern Time on March 13, 2026, with split-adjusted trading expected to begin on March 16, 2026, under a new CUSIP number.

• Aimed at Nasdaq Compliance

  The reverse split is intended to increase the per share trading price of the common stock to regain compliance with The Nasdaq Capital Market's minimum bid price requirement for continued listing.

auto_awesomeAnalysis

This 8-K reports the critical outcome of Harvard Bioscience's Special Meeting, where stockholders approved a reverse stock split. The Board subsequently set the ratio at 1-for-10, effective March 13, 2026, with split-adjusted trading beginning March 16, 2026. This action is explicitly intended to boost the per-share price to regain compliance with Nasdaq's minimum bid price requirement, preventing a potential delisting. While necessary for continued listing, reverse splits are generally viewed negatively by the market as they often signal underlying financial challenges or a lack of investor confidence, as the company's fundamental value remains unchanged. Investors should monitor the stock's performance post-split and the company's ability to sustain compliance.